Molecular Signatures and Precision Medicine of Gastric Cancer
Received Date: Feb 26, 2019 / Accepted Date: May 27, 2019 / Published Date: Jun 03, 2019
Gastric cancer (GC) is the fifth most commonly diagnosed cancer worldwide and the second leading cause of cancer-related deaths. Adenocarcinoma accounts for approximately 95% of all malignant gastric neoplasms. Most localized GC (stages II and III) are best treated with multimodality therapy with a 5-year survival in approximately 40% of patients; however, advanced GC only has limited treatment options with poor prognosis. GC is a highly heterogenous disease. Historically, many classification systems have been proposed, including anatomical classification (Borrmann classification, Siewert and Stein classification), histological classification (WHO classification, Laurén’s classification), and extent of disease (early gastric cancer vs. advanced cancer). Originally proposed in 1965, the Laurén’s classification divides GC into intestinal- and diffuse-types that are quite distinct in the histological features, epidemiology, and etiology.
Keywords: Gastric cancer; HER2; Microsatellite instability; PD-L1; CDH1; Cancer immunotherapy
Citation: Zhang L, Luo W, Cao A, Tan D (2019) Molecular Signatures and Precision Medicine of Gastric Cancer. J Mol Genet Med 13: 429.
Copyright: © 2019 Zhang L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
- Total views: 677
- [From(publication date): 0-0 - Nov 15, 2019]
- Breakdown by view type
- HTML page views: 633
- PDF downloads: 44